Understanding where a patient falls along the spectrum of liver disease shouldn’t require invasive procedures or fragmented data. The OWLiver® test provides a clear, non-invasive way to assess liver health — helping clinicians identify risk earlier and act with confidence.
OWLiver analyzes a panel of advanced metabolites along with BMI, ALT and AST to generate a MASEF and MASH score and deliver a comprehensive view of liver status. The test is uniquely designed to not only identify patients at higher risk of disease progression, but also enables more precise clinical decision-making.
How the OWLiver Test Works
The OWLiver test combines the output of two validated algorithms1 to classify patients across all treatable stages of MASLD. First, the MASH with significant fibrosis algorithm is applied. Patients meeting the threshold are identified as at risk for progression. If that threshold is not met, a second algorithm further distinguishes between MASH and no MASLD/steatosis. The result is a visual, intuitive report that clearly shows where a patient sits along the liver health continuum — without a biopsy.
When clinicians can see the entire story of liver health at a glance, conversations change from uncertainty to clarity, and from delayed action to timely intervention.
“When you see the whole story, you can change the ending.”
See It for Yourself
The best way to understand the value of OWLiver is to view the report firsthand.
References
1 Noureddin, M. et al. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF). Hepatology 79, 135–148 (2024).
1Mincholé, I. et al. Serum metabolomics-based steatohepatitis score for the non-invasive identification of patients with non-alcoholic steatohepatitis (NASH) in multiethnic, including type 2 diabetes mellitus population. in J Hepatol, vol. 75, Suppl. 2 (2021).